Composition and methods for treating or preventing degenerative joint and cardiovascular conditions

Abstract

A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and / or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed.

Description

FIELD OF THE INVENTION[0001]The subject of this invention relates to compositions and methods of treatment and prevention of degenerative and / or cardiovascular conditions.BACKGROUND OF THE INVENTION[0002]Degenerative joint disorders is a painful degenerative condition that results in the detcrioration of cartilage tissues that support the weight-bearing joints in the body. Once the cartilage is thinned or lost, the constant grinding of bones against each other causes pain and stiffness around the joint. Abnormal and excess bone formations called spurs grow from the damaged bones, causing further pain and stiffness. It is believed that degenerative joint disorders affect 80% of people over the age of 60. Degenerative joint disorders include, for example, osteoarthritis, rheumatoid arthritis, other rheumatic disorders with cartilage breakdown, chondrolysis after joint trauma, for example, after meniscus or patella injuries or torn ligaments, or chondrolysis associated with prolonged i...

AI Technical Summary

Benefits of technology

[0010]In embodiments, a method for treating and / or reducing a risk of a cardiovascular disease in a subject in need thereof is provided. The method comprises providing a formulation comprising polycosanols, at least about 10 milligrams of chondroitin per milligram of the polycosanols, at least about 10 milligrams of glucosamine per milligram polycosanols, optionally at least about 10 milligrams of PABA per milligram of the polycosanols and optionally at least about 0.005 milligrams of folic acid per milligram polycosanols. The method provides for orally administering to the subject for a therapeutically effective period of time a therapeutically effective amount of the formulation.

[0011]In embodiments, a composition for treating and / or reducing a risk of a degenerative joint disorder in a subject in need thereof is provided. The composition comprises polycosanols, at least about 10 milligrams of chondroitin per milligram of the polycosanols, at least about 10 milligrams of glucosamine per milligram polycosanols, optionally at least about 10 milligrams of PABA per milligram of the polycosanols and optionally at least about 0.005 milligrams of folic acid per milligram polycosanols. The polycosanols comprise at least two fatty alcohols selected from tetracosanol, hexacosanol, octacosanol and triacontanol.

[0012]In embodiments, a method for treating and / or reducing a risk of a degenerative joint disorder in a subject in need thereof is provided. The method comprises providing a formulation comprising polycosanols, at least about 10 milligrams of chondroitin per milligram of the polycosanols, at least about 10 milligrams of glucosamine per milligram polycosanols, optionally at least about 10 milligrams of PABA per milligram of the polycosanols and optionally at least about 0.005 milligrams of folic acid per milligram polycosanols. The polycosanols comprise at least two fatty alcohols selected from tetracosanol, hexacosanol, octacosanol and triacontanol. The method provides for orally administering to the subject for a therapeutically effective period of time a therapeutically effective amount of the formulation.

Problems solved by technology

Once the cartilage is thinned or lost, the constant grinding of bones against each other causes pain and stiffness around the joint.

Abnormal and excess bone formations called spurs grow from the damaged bones, causing further pain and stiffness.

Osteoarthritis usually develops in joints that are injured by repeated overuse in the performance of a particular job or a favorite sport or from carrying around excess body weight.

Eventually this injury or repeated impact thins or wears away the cartilage that cushions the ends of the bones in the joint so that the bones rub together, causing a grating sensation.

In rheumatoid arthritis, these enzymes destroy the linings of joints causing pain, swelling, stiffness, deformity, and reduced movement and function.

The ischemia damages the organs in which it develops because it impairs the functions of mitochondria that produce adenosine triphosphate (ATP).

The resulting functional damage of organs can be fatal if it occurs in vital organs such as the heart, brain and blood vessels.

Antiarrhythmic agents have been used to treat ischemic heart disease and arrhythmia, but their use with patients with possible cardiac failure has been limited because these agents may cause cardiac arrest by their cardiodepressant effects.

Atherosclerosis is often complicated by one or more cardiovascular diseases and can make the patient seriously ill.